The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment

Seminars in Arthritis and Rheumatism

Volumn 28, Issue 4, 1999, Pages 211-267

  Ghosh, P ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Osteoarthritis; Pentosan polysulfate; Structural modifying osteoarthritis drugs (SMOADs); Treatment

Indexed keywords

PENTOSAN POLYSULFATE;

CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; HUMAN; NONHUMAN; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0032964167     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-0172(99)80021-3     Document Type: Article

References (390)

1. Scott J.C. Hochberg M.C. Arthritic and other musculoskeletal disease Brownson R.C. Remington P.L. Davis J.L. Chronic disease epidemiology 1993 American Public Health Association Washington, DC
2. Croft P. The occurrence of osteoarthritis outside Europe Ann Rheum Dis 55 1996 661 664
3. Felson D.T. Epidemiology of hip and knee osteoarthritis Epidermal Rev 10 1988 1 28
4. Petersson I.F. Occurrence of osteoarthritis of the peripheral joints in European populations Ann Rheum Dis 55 1996 659 661
5. Felson D.T. Osteoarthrids Rheum Dis Clin North Am 16 1990 499 512
6. Ruchlin H.S. Elkin E.B. Paget S.A. Assessing costeffectiveness analyses in rheumatoid arthritis and osteoarthritis Arthritis Care Research 10 1997 413 421
7. Altman R. Asch E. Bloch D. Bole G. Borestein D. Brandt K. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee Arthritis Rheum 29 1986 1039 1049
8. Altman R. Alarcon G. Appelrouth D. Bloch D. Borenstein D. Brandt K. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand Arthritis Rheum 33 1990 1601 1610
9. Hulth A. Does osteoarthrosis depend on growth of the mineralized layer of cartilage Clin Orthop 287 1993 19 24
10. Burr D.B. Schaffler M.B. The involvement of subchondral mineralized tissues in osteoarthrosis: quantitative microscopic evidence Microsc Res 37 1997 343 357
11. Matsui H. Shimizu M. Tsuji H. Cartilage and subchondral bone interaction in osteoarthrosis of human knee joint: a histological and histomorphometric study Macrosc Res 37 1997 333 342
12. Sokoloff L. Pathology and pathogenesis of osteoarthritis McCarty D. Arthritis and Allied Conditions 1979 Lea & Febiger Philadelphia 1135 1153
13. Fazzalari N.L. Darracott J. Vernon-Roberts B. Histomorphometric changes in the trabecular structure of a selected stress region in the femur in patients with osteoarthritis and fracture of the femoral neck Bone 6 1985 125 133
14. Cheras P.A. Freemont A.J. Sikorski J.M. Intraosseous thrombosis in ischemic necrosis of bone and osteoarthritis Osteoarthritis Cart 1 1993 219 232
15. Bullough P.G. DiCarlo E.F. Subchondral avascular necrosis: a common cause of arthritis Ann Rheum Dis 49 1990 412 420
16. Kiaer T. The intraosseous circulation and pathogenesis of osteoarthritis Med Sci Res 15 1987 759 763
17. Wong S.Y.P. Evans R.A. Needs C. Dunstan C.R. Hills E. Garvan J. The pathogenesis of osteoarthritis of the hip: evidence for primary osteocyte death Clin Orthop 214 1987 305 312
18. 2, pressure, pH, and lactate in human osteoarthritis of the hip Clin Orthop 229 1988 149 155
19. Kiaer T. Intraosseous concentrations of lactate in late stage of osteoarthritis of the hip IRCS Med Sci 14 1986 591 592
20. Glant T.T. Fülöp C. Cs-Szabó G. Buzas E. Ragasa D. Mikecz K. Mapping of arthritogenic/autoimmune epitopes of cartilage aggrecans in proteoglycan-induced arthritis Scand J Rheumatol 24 1995 43 49
21. Rowley M. Tait B. Mackay I.R. Cunningham T. Phillips B. Collagen antibodies in rheumatoid arthritis: significance of antibodies to denatured collagen and their association with HLA-DR4 Arthritis Rheum 29 1986 174 184
22. Seibel M.J. Jelsma R. Saed-Nejad F. Ratcliffe A. Variability in the immunochemical quantification of keratan sulfate in human and bovine cartilage proteoglycans Biochem Soc Trans 18 1990 969 970
23. Lindblad S. Hedfors E. Arthroscopic and immunohisto-logic characterization of knee-joint synovitis in osteoarthritis Arthritis Rheum 30 1987 1081 1088
24. Soren A. Osteoarthritis: an arthritis? Z Rheumatol 41 1982 1 6
25. Revell P.A. Mayston V. Lalor P. Mapp P. The synovial membrane in osteoarthritis: a histological study including the characterization of the cellular infiltrate present in inflammatoryosteoarthritis using monoclonal antibodies Ann Rheum Dis 47 1988 300 307
26. Smith M.D. Triantafillou S. Parker A. Youssef P.P. Coleman M. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis J Rheumatol 24 1997 365 371
27. Müller-Ladner U. Gay R.E. Gay S. Structure and function of synoviocytes Koopman W.J. Arthritis and allied conditions 1997 Williams & Wilkins Baltimore 243
28. Edwards J.C.W. The nature and origins of synovium: experimental approaches to the study of synoviocyte differentiation J Anat 184 1994 493 501
29. Balazs E.A. The physical properties of synovial fluid and the special role of hyaluronic acid Helfet A.J. Disorders of the knee 1982 Lippincott Philadelphia 61 74
30. Pelletier J-P. DiBattista J.A. Roughley P. McCollum R. Martel-Pelletier J. Cytokines and inflammation in cartilage degradation Rheum Dis Clin North Am 19 1993 545 568
31. Dean D.D. Proteinase-mediated cartilage degradation in osteoarthritis Semin Arthritis Rheum 20 1991 2 11
32. Blake D.R. Allen R.E. Lunec J. Free radicals in biological systems: a review orientated to inflammatory processes Br Med Bull 43 1987 371 385
33. Davies M.G. Fulton G.J. Hagen P-O. Clinical biology of nitric oxide Br J Surg 82 1995 1598 1610
34. Salvemini D. Seibert K. Marino M.H. New concepts in inflammation and therapy Drug News P 9 1996 204 219
35. Hutadilok N. Ghosh P. Brooks P.M. Binding of haptoglobin, inter-alpha-trypsin inhibitor, and alpha-l-proteinase inhibitor to synovial fluid hyaluronate and the influence of these proteins on its degradation by oxygen derived free radicals Ann Rheum Dis 47 1988 377 385
36. Weinberger A. Simkin P.A. Plasma proteins in synovial fluids of normal human joints Semin Arthritis Rheum 19 1989 66 76
37. Evans C.H. Watkins S.C. Stefanovic-Racic M. Nitric oxide and cartilage metabolism Methods Enzymol 269 1996 75 88
38. Brandt K.D. NSAIDs in the treatment of osteoarthritis: friends or foes Bull Rheum Dis 42 1993 1 4
39. Brandt K.D. Should nonsteroidal antiinflammatory drugs be used to treat osteoarthritis Rheum Dis Clin North Am 19 1993 29 44
40. Brandt K.D. Slowman-Kovacs S. Nonsteroidal antiinflammatory drugs in treatment of osteoarthritis Clin Orthop 213 1986 84 91
41. Gabriel S.E. Fehring R.A. Trends in the utilization of non-steroidal anti-inflammatory drugs in the United States, 1986–1990 J Clin Epidemiol 45 1992 1041 1044
42. Gabriel S.E. Wagner J.L. Costs and effectiveness of nonsteroidal anti-inflammatory drugs: the importance of reducing side effects Arthritis Care Res 10 1997 56 63
43. Dieppe P. Cushnaghan J. Jasani M.K. McCrae F. Watt I. A two year, placebo-controlled trial of non-steroidal anti-inflammatory therapy in osteoarthritis of the knee joint Br J Rheumatol 32 1993 595 600
44. Gabriel S.E. Jaakkimainen L. Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis Ann Intern Med 115 1991 787 796
45. Lichtenstein D.R. Syngal S. Wolfe M.M. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract: the doubleedged sword Arthritis Rheum 38 1995 5 18
46. Davies M.N. Wallace J.L. Nonsteroidal anti-inflammatory drug-induced gastrointestinal toxicity: new insights into an old problem J Gastroenterol 32 1997 127 133
47. Peterson M.G.E. Kovar-Toledano P.A. Otis J.C. Allegrante J.P. Mackenzie C.R. Gutin B. Effect of a walking program on gait characteristics in patients with osteoarthritis Arthritis Care Res 6 1993 11 16
48. Manoukian A.V. Carson J.L. Nonsteroidal anti-inflammatory drug-induced hepatic disorders: incidence and prevention Drug Safety 15 1996 64 71
49. Huskisson E.C. Berry H. Gishen P. Jubb R.W. Whitehead J. Effects of anti-inflammatory drugs on the progression of osteoarthritis of the knee J Rheumatol 22 1995 1941 1946
50. Fu J.Y. Musferrer J.L. Seibert K. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes J Biol Chem 265 1990 16737 16740
51. Akarasereenont P. Mitchell J.A. Thiemermann C. Vane J.R. Relative potency of non-steroid antiinflammatory drugs as inhibitors of cycloxygenase-1 and cycloxygenase-2 Br J Pharmacol 112 1994 183
52. Sirios J. Richards J.S. Purification and characterization of a novel, distinct isoform of prostaglandin endoperoxide sythase induced by human chorionic gonadotropin ingranulosa cells of rat preovulatory follicles J Biol Chem 267 1992 6382 6388
53. Vane J.R. Botting R.M. Mechanism of action of anti-inflammatory drugs Scand J Rheumatol 25 1996 9 21
54. Meade E.A. Smith W.L. DeWitt D.L. Differential inhibition of prostaglandin endoperoxidase synthase (cyclooxygenase) isoenzymes by aspirin and other non-steroidal antiinflammatory drugs J Biol Chem 268 1993 6610 6614
55. Mitchell J.A. Akarasereenont P. Thiemermann C. Flower R.J. Vane J.R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase Proc Natl Acad Sci USA 90 1993 1693 1697
56. Engelhardt G. Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2 Br J Rheumatol 35 1996 4 12
57. Noble S. Balfour J.A. Meloxicam Drugs 51 1996 424 443
58. Engelhardt G. Homma D. Schlegel K. Utzmann R. Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance Inflamm Res 44 1995 423 433
59. 2 inhibits the release of tumor necrosis factor-α, rather than interleukin 1 β, from human macrophages Immunol Lett 31 1991 85 90
60. 1 inhibit cytokine-induced metalloprotease expression in human synovial fibroblasts: mediation by cyclic-AMPsignalling pathway Lab Invest 71 1994 270 278
61. Knudsen P.J. Dinarello C.A. Strom T.B. Prostaglandins posthanscriptionally inhibit monocyte expression of interleukin-1 activity by increasing intracellular cyclic adenosine monophosphate J Immunol 137 1986 3189 3194
62. 2 regulates inducible nitric oxide synthease in the murine macrophage cell line J774 Prostaglandin 49 1995 105 115
63. 2 stimulates incorporation of proline into collagenase digestible proteins in human articular chondrocytes: identification of aneffector autocrine loop involving insulin-like growth factor 1 Mol Cell Endocrinol 123 1996 27 35
64. Bassleer C. Magotteaux J. Geenen V. Malaise M. Effects of meloxicam compared to acetylsalicyclic acid in human articular chondrocytes Pharmacology 54 1997 49 56
65. Dingle JT. The effect of NSAID on human articularcartilage. Glycosaminoglycan synthesis. Osteoarthritis Cart (in press).
66. Mohr W. Lehmann H. Engelhardt G. Chondroneutrality of meloxicam in rats with spontaneous ostenarthosis of the ankle joint Z Rheumatol 56 1997 21 30
67. Ghosh P. Nonsteroidal anti-inflammatory drugs and chondroprotection: a review of the evidence Drugs 46 1993 834 846
68. Meyer-Carrive I. Ghosh P. Effects of tiaprofenic acid (Surgam) on cartilage proteoglycans in the rabbit joint immobilisation model Ann Rheum Dis 51 1992 448 455
69. Dingle J.T. Cartilage maintenance in osteoarthritis: interaction of cytokines, NSAID and prostaglandins in articular cartilage damage and repair J Rheumatol 18 1991 30 37
70. Burkhardt D. Ghosh P. Laboratory evaluation of glycosaminoglycan polysulphate ester for chondroprotective activity Curr Ther Res 40 1986 1034 1053
71. Ghosh P. Anti-rheumatic drugs and cartilage Brooks P.M. Bailliere's clinical rheumatology international practice and research 1988 Bailliere Tindall London 309 338
72. Ghosh P. Smith M. Wells C. Second line agents in osteoarthritis Dixon J.S. Furst D.E. Second Line Agents in the Treatment of Rheumatic Diseases 1992 Dekker New York 363 427
73. McNamara P.S. Spencer D.V.M. Johnston S.A. Todhunter R.J. Slow acting, disease modifying osteoarthritis agents Vet Clin North Am Small Anim Pract 27 1997 863 881
74. Howell D.S. Altman R.D. Pelletier J-P. Martel-Pelletier J. Dean D.D. Disease-modifying antirheumatic drugs: current status of their application in animal models of osteoarthritis Kuettner K. Goldberg V. Osteoarthritis Disorders Am Acad Orthop Surg 1995 365 377
75. Altman R. Brandt K. Hochberg M. Moskowitz R. Bellamy N. Bloch D.A. Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society Osteoarthritis Cart 4 1996 217 243
76. Odlind B. Dencker L. Tengblad A. Preferential localization of 3H-pentosanpolysulphate to the urinary tract in rats Pharmacol Toxicol 61 1987 162 166
77. Fellström B. Björklund U. Danielson B.G. Eriksson H. Odlind B. Tengblad A. Pentosan polysulphate (Elmiron): pharmacokinetics and effects of the urinary inhibition of crystal growth Proceedings of the Harnstein-Symposum March 2022 Bonn 1986 340 344
78. Klöcking H-P. Hauptmann J. Richter M. Profibrinolytic and anticoagulant properties of the pentosan polysulphate derivative bego 0391 Pharmazie 46 1991 543 544
79. Klöcking H-P. Ageing and t-PA relase by calcium and sodium pentosan polysulphate after oral application in rats Fibrinolysis 6 1992 42 43
80. (personal communication from Dr M Scholz; Benechemie, Munich) Breddin H.K. Geidrojc J. A comparative study of the anti-thrombotic effects of calcium and sodium xylopyranose polysulphate in a rat injury model using subcutaneous andoral routes of administration 1994
81. Bowman L. Jackson C. Smith M.M. Ghosh P. Calcium pentosan polysulphate (CaPPS) stimulates release of superoxide dismutase (SOD) from endothelium in vitro and in vivo 7th Biennial Scientific Meeting of the International Society for Free Radical Research November 6–10, 1994 NWS Sydney
82. Verbruggen G. Veys E.M. Laboratory and clinical studies on calcium pentosan polysulphate Osteoarthritis Cart 4 1996 iii iv
83. Jacobsson O. Kiiver T. Granath K. Characterization of xylansulfate by size exclusion chromatography J Liquid Chromatogr 9 1986 1549 1561
84. Melrose J. Ghosh P. Determination of the average molecular size of glycosaminoglycans by fast protein liquid chromatography J Chromatogr 637 1993 91 95
85. Mow V.C. Ratcliffe A. Poole A.R. Cartilage and diarthrodial joints as paradigms for hierarchical materials and structures Biomaterials 13 1992 67 97
86. Rosenberg L. Tang L.H. Choi H.U. Johnson T. Biological functions of dermatan sulphate proteoglycans Scott J.E. Dermatan sulphate proteoglycans: chemistry, biology, chemical pathology 1993 Portland Press London 225 239
87. Scott J.E. The periphery of the developing collagen fibril: quantitative relationship with dermatan sulphate and other surface-associated species Biochem J 218 1984 229 233
88. Lewandowska K. Choi H.U. Rosenberg L.C. Zardi L. Culp L.A. Fibronectin-mediated adhesion of fibroblasts: inhibition by dermatan sulfate proteoglycan and evidence for a cryptic glycosaminoglycan-binding domain J Cell Biol 105 1987 1443 1454
89. Kresse H. Hausser H. Schönherr E. Small proteoglycans Experientia 49 1993 403 416
90. Vogel K.G. Paulsson M. Heinegåxd D. Specific inhibition of type 1 and type 2 collagen fibrillogenesis by the proteoglycan of tendon Biochem J 223 1984 587 597
91. Vogel K.G. Evanko S.P. Proteoglycans of fetal bovine tendon J Biol Chem 262 1987 13607 13613
92. Visser N.A. Vankampen G.P. Dekoning M.H. Vanderkorst J.K. The effects of loading on the synthesis of biglycan and decorin in intact mature articular cartilage in vitro Connect Tissue Res 30 1994 241 250
93. Little C.B. Ghosh P. Bellenger C.R. Topographic variation in biglycan and decorin synthesis by articular cartilage in the early stages of osteoarthritis: an experimental study in sheep J Orthop Res 14 1996 433 444
94. Brinckerhoff C.E. Joint destruction in arthritis: metalloproteinases in the spotlight Arthritis Rheum 34 1991 1073 1075
95. Altman R.D. Pita J.C. Howell D.S. Degradation of proteoglycans in human osteoarthritic cartilage Arthritis Rheum 16 1973 179 185
96. Martel-Pelletier J. McCollum R. Fujimoto N. Obata K. Cloutier J-M. Pelletier J-P. Excess of metalloproteases over fissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis Lab Invest 70 1994 807 815
97. Okada Y. Shinmei M. Tanaka O. Naka K. Kimura A. Nakanishi I. Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium Lab Invest 66 1992 680 690
98. March Cawston T. Matrix metalloproteinases and TIMPs: properties and implications for the rheumatic diseases Mol Med Today 1998 130 137
99. Hughes C. Murphy G. Hardingham T.E. Metalloproteinase digestion of cartilage proteoglycan: pattern of cleavage by stromelysin and susceptibility to collagenase Biochem J 279 1991 733 739
100. Birkedal-Hansen H. Moore W.G.I. Bodden M.K. Windsor L.J. Birkedal-Hansen B. DeCarlo A. Matrix metalloproteinases: a review Crit Rev Oral Biol 4 1993 197 250
101. Flannery C.R. Lark M.W. Sandy J.D. Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan: evidence for proteolysis at this site in vivo inhuman articular cartilage J Biol Chem 267 1992 1008 1014
102. Fosang A.J. Last K. Maciewicz R.A. Aggrecan is degraded by matrix metalloproteinases in human arthritis: evidence that matrix metalloproteinase and aggrecanase activities can be independent J Clin Invest 98 1996 2292 2299
103. Hughes C.E. Caterson B. Fosang A.J. Roughley P.J. Mort J.S. Monoclonal antibodies that specifically recognize neoepitope sequences generated by aggrecanase and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro Biochem J 305 1995 799 804
104. Bayne E.K. MacNaul K.L. Donatelli S.A. Christen A. Griffin P.R. Hoermer L.A. Use of an antibody against the matrix metalloproteinase-generated aggrecan nenepitope FVDIPEN-COOH to assess the effects of stromelysin in a rabbitmodel of cartilage degradation Arthritis Rheum 38 1995 1400 1409
105. Sandy J.D. Flannery C.R. Neame P.J. Lohmander L.S. The structure of aggrecan fragments in human synovial fluid: evidence for the involvement in osteoarthrits of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain J Clin Invest 89 1992 1512 1516
106. Lohmander L.S. Neame P.J. Sandy J.D. The structure of aggrecan fragments in human synovial fluid: evidence that aggrecanase mediates cartilage degradation in inflammatory jointdisease, joint injury, and osteoarthritis Arthritis Rheum 36 1993 1214 1222
107. Buttle D.J. Handley C.J. Ilic M.Z. Saklatvatvala J. Murata M. Barrett A.J. Inhibition of cartilage proteoglycan release by a specific inactivator of cathepsin-B and an inhibitor of matrix metalloproteinases: evidence fortwo converging pathways of chondrocyte-mediated proteoglycan degradation Arthritis Rheum 36 1993 1709 1717
108. Chubinskaya S. Cs-Szabo G. Myer R. Kuettner K.E. ADAM-10 is expressed in human articular cartilage Trans Orthop Res Soc 23 1998 79
109. Tortorella M.D. Pratta M.A. Fox J.W. Arner E.C. The interglobular domain of cartilage aggrecan is cleaved by hemorrhagic metalloproteinase HT-D (atrolysin C) at the matrix metalloproteinase andaggrecanase sites Trans Orthop Res 23 1998 81
110. Büttner F.H. Chubinskaya S. Margerie D. Huch K. Flechtenmacher J. Cole A.A. Expression of membrane type I matrix metalloproteinase in human articular cartilage Arthritis Rheum 40 1997 704 709
111. Büttner F.H. Hughes C.E. Margerie D. Lichte A. Tschesche H. Caterson B. The catalytic domain of membrane type 1 matrix metalloproteinase (MT1-MMP) cleaves the recombinant aggrecan IGD substrate (raggimut) at the‘aggrecanase’-site Trans Orthop Res Soc 23 1998 84
112. Kalbhen D.A. Biochemically induced osteoarthritis in the chicken and rat Munthe E. Bjelle A Effects of drugs on osteoarthritis 1984 Hans Huber, Berne, Stuttgart, Vienna 48 68
113. Costeseque R. Emonds-Alt X. Breliere J.C. Roncucci R. Polysulphated polysaccharides: an in vitro study of their effects on proteoglycan biosynthesis by articular chondrocytes Arch Int Pharmacodyn Ther 282 1986 196 208
114. Collier S. Ghosh P. Evaluation of the effects of antiarthritic drugs on the secretion of proteoglycans by lapine chondrocytes using a novel assay procedure Ann Rheum Dis 48 1989 372 381
115. Anderson J.M. Edelman J. Ghosh P. Effects of pentosan polysulfate on peripheral blood leukocyte populations and mononuclear cell procoagulant activity in patients withosteoarthritis Curr Ther Res 58 1997 93 107
116. Ghosh P. Medved H. Bansal M. Haynes D. Whitehouse M. In vitro evaluation of action of anti-rheumatic drugs Osteoarthritis Cartilage 1 1993 10
117. Smith M.M. Ghosh P. The dose-dependent effects of calcium xylopyranose polysulphate on the metabolism of ovine articular chondrocytes Proceedings of the Matrix Biology Society of Australia and New Zealand 1 1997 S8
118. Aydelotte M.B. Kuettner K.E. Differences between subpopulations of cultured bovine articular chondrocytes: morphology and cartilage matrix production Connect Tissue Res 18 1988 205 222
119. Raiss R.X. Karbowski A. Aigner T. Schleyerbach R. Chondrocytes and anthheumatic drugs J Rheumatol 22 1995 152 154
120. Roughley P.J. Lee E.R. Cartilage proteoglycans: structure and potential functions Microsc Res 28 1994 385 397
121. Verbruggen G. Cornelissen M. Malfait A.M. Broddelez C. De Ridder L. Veys E.M. Aggrecans synthesized by human chondrocytes cultured in suspension culture in agarose: relation to ageing Osteoarthritis Cartilage 5 1997 29
122. Verbruggen G. Cornelissen M. Broddelez C. Veys E.M. Polysulfated polysaccharides increase the molecular size of aggrecan aggregates synthesized by human chondrocytes cultured in gelified agarose Osteoarthritis Cartilage 5 1997 61
123. Mohtai M. Smith R.P. Schurman D.J. Tsuji Y. Torti F.M. Hutchinson N.I. Expression of 92-KD type-IV collagenase gelatinase (gelatinase-B) in osteoarthrrtic cartilage and its induction in normal human articular cartilageby interleukin-1 J Clin Invest 92 1993 179 185
124. Hollander A.P. Heathfield T.F. Webber C. Iwata Y. Bourne R. Rorabeck C. Increased damage to type II collagen in osteoarthrrtic articular cartilage detected by a new immunoassay J Clin Invest 93 1994 1722 1732
125. Billinghurst R.C. Dahlberg L. Ionescu M. Reiner A. Bourne R. Rorabeck C. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage J Clin Invest 99 1997 1534 1545
126. Shlopov B.V. Lie W.R. Mainardi C.L. Cole A.A. Chubinskaya S. Hasty K.A. Osteoarthritic lesions: involvement of three different collagenases Arthritis Rheum 40 1997 2065 2074
127. Werb Z. Degradation of collagen Weiss J.B. Jayson M.I.V. Collagen in health and disease 1982 Churchill Livingston New York 121 134
128. Barrett A.J. Capacity of leucocyte elastase and cathepsin G to degrade mature collagen fibers Havemann K. Janoff A. Neutral proteases of human polymorphonuclear leukocytes: biochemistry, physiology and clinical significance 1978 Urban and Schwarzenberg Baltimore 385 389
129. Nagase H. Activation mechanisms of matrix metalloproteinases Biol Chem 378 1997 151 160
130. Buddecke E. Platt D. Untersuchungen zur Chemie der Arterienwand VIII Nachweis, Reinigung and Eigenschaften der Hyalmonidase aus der Aorta des Rindes Hoppe-Seylers Zeitschrift fur Physiologische Chemie 343 1965 61 79
131. Buddecke E. Werries E. Untersuchungen zur Chemie der Arterienwand Reinigung und Eigenschaften der B-Acetylglucosaminidase aus der Aorta des Rindes Hoppe-Seylers Zeitschrift fur Physiologische Chemie 340 1965 257 272
132. Parish C.R. Coobe D.R. Jakobsen K.D. Bennett F.A. Underwood P.A. Evidence that sulphated polysaccharides inhibit tumour metastasis by blocking tumour-cell-derived heparinase Int J Cancer 40 1987 511 518
133. Herbert J-M. Maffrand J-P. Effect of pentosan polysulphate, standard heparin and related compounds on protein kinase C activity Biochim Biophys Acta 109 1991 432 441
134. Arner E.C. Pratta M.A. Modulation of interleukin-linduced alterations in cartilage proteoglycan metabolism by activation of protein kinase-C Arthritis Rheum 34 1991 1006 1013
135. Takahashi S. Sato T. Ito A. Ojima Y. Hosono T. Nagase H. Involvement of protein-kinase-C in the interleukin-1 alpha-induced gene expression of matrix metalloproteinases and tissue inhibitor-1 ofmetalloproteinases (TIMP 1) in human uterine cervical fibroblasts Bioc Biop A1220 1993 57 65
136. 2 from mouse osteoblast-like cell line, MC3T3El Biochim Biophys Acta 1221 1994 78 82
137. Kruze D. Fehr K. Menninger H. Boni A. Böni A.0679 0 0679 0 Effect of antirheumatic drugs on neutral protease from human leucocyte granules Zeitschrift fur Rheumatologie 35 1976 337 346
138. Kruze D. Salgam P. Fehr K. Boni A. Böni A.0679 0 0679 0 Degradation of bovine nasal cartilage by a neutral protease from human leukocyte granules Willoughby D.A. Giroud T.P. Velo G.P. perspectives in inflammation: future trends and developments Lancaster 1997 MTP Press England 361 370
139. Andrews J.L. Ghosh P. Lentini A. Temai B. Ternai B.0679 0 0679 0 The interaction of pentosan polysulfate (SP54) with human neutrophil elastase and connective tissue matrix components Chem Biol Interact 47 1983 157 173
140. Baici A. Salgam P. Fehr K. Boni A. Böni A. Inhibition of human elastase from polymorphonuclear leucocytes by gold sodium thiomalate and pentosan polysulfate (SP-54®) Biochem Pharmacol 30 1981 703 708
141. Steinmeyer J. Kalbhen D.A. Influence of some natural and semisynthetic agents on elastase and cathepsin G from polymorphonuclear granulocytes Arzneimittelforschung 41 1991 77 80
142. Barg W.F. Englert M.E. Buermann C.W. Oronsky A.L. Kerwar S.S. Studies on the effect of pentosan polysulfate on proteoglycan degradation by leukocyte neutral proteases Biochem Pharmacol 28 1979 2639 2643
143. Lentini A. Ternai B. Ghosh P. The interaction of heparin and SP54 with gelatin Int J Biol Macromol 10 1988 113 120
144. Mathies H. Willms D. Vergleichende Untersuchungen der Einwirkung von Heparin and SP54 auf das Farbstoff-Hyaluronidase-Spreading Med Monatsschr Pharm 19 1965 38 39
145. Kalbhen D.A. Karzel K. Dinnendahl V. Domenjoz R. Effects of natural and semisynthetic polysaccharides on connective tissue metabolism Arzneimittelforschung 20 1970 1479 1482
146. Frost G.L. Csoka T. Stern R. The hyaluronidases: a chemical, biological and clinical overview Trends in Glycoscience and Glycotechnology 8 1996 419 434
147. (accepted for presentation) Ghosh P. Xu A. Little C. Modulation of matrix metalloproteinase activities in osteoarthritic cartilage by calcium xylopyranose polysulfate Combined Orthop Res Soc Meeting Hamamatsu, Japan September 28–30, 1998
148. Platt D. Zur Beeinflussung des katabolen Mucopolysaccharidstoffwechsels durch SP54 Med Welt 23 1972 1767 1768
149. Leiss C. Kalbhen D.A. Untersuchungen uber den durch leukozytare Enzyme stimulierten Abbau von norpelgewebe and seine Beeinflussung durch antirheumatische Arzneimittel Arzneimittelforschung 26 1976 165 169
150. Kruze D. Menninger H. Fehr K. Boni A. Böni A. Purification and some properties of a neutral protease from human leukocyte granules and its comparison with pancreatic elastase Biochim Biophys Acta 438 1976 503 513
151. Kruze D. Fehr K. Boni A. Böni A. Effect of antirheumatic drugs on cathepsin B1 from bovine spleen Z Rheumatol 35 1976 95 102
152. Rogachefsky R.A. Dean D.D. Howell D.S. Altman R.D. Treatment of canine osteoarthritis with insulin-like growth factor-1 (IGF-1) and sodium pentosan polysulfate Osteoarthritis Cart 1 1993 105 114
153. Grumbles R.M. Howell D.S. Howard G.A. Roos B.A. Setton L.A. Mow V.C. Cartilage metalloproteases in disuse atrophy J Rheumatol 22 1995 146 148
154. Nethery A. Giles I. Jenkins K. Jackson C. Brooks P. Burkhardt D. The chondroprotective drugs, arteparon and sodium pentosan polysulphate,increase collagenase activity and inhibit stromelysin activity in vitro Biochem Pharmacol 44 1992 1549 1553
155. Grumbles R.M. Shao L. Jeffrey J.J. Howell D.S. ILl-B stimulated collagenase-3 gene upregulation chondrocytes: suppression by pentosan polysulfate Trans Orthop Res Soc 23 1998 917
156. Grumbles R.M. Shao L. Jeffrey J.J. Howell D.S. Regulation of rat interstitial collagenase gene expression in growth cartilage and chondrocytes by vitamin D-3, interleukin-1-beta, and okadaicacid J Cell Biol 63 1996 395 409
157. Busch S.J. Martin G.A. Barnhart R.L Mano M. Cardin A.D. Jackson R.L. Trans-repressor activity of nuclear glycosaminoglycans on Fos and Jun/AP-1 oncoprotein-mediated transcription J Cell Biol 116 1992 31 42
158. Golding J.C. Ghosh P. Drugs for osteoarthrosis 1: the effects of pentosan polysulphate (SP54) on the degradation and loss of proteoglycans from articular cartilage in a model of osteoarthrosis induced in the rabbit knee joint by immobilization Curr Ther Res 33 1983 173 184
159. Kalbhen D.A Blum U. Theoretisches Konzept and experimentelle Bestatigung for ein Arthrose-Modell am Versuchstier Arzneimittelforschung 27 1977
160. Howell D.S. Kapila P. Malinin T.I. Altman R.D. Cartilage degradation and repair: a brief review of chondroprotective treatment Excerpta Medica 3 1987 13
161. (Suppl) Malemud C.J. Goldberg V.M. Moskowitz R.W. Pathological, biochemical and experimental therapeutic studies in meniscectomy models of osteoarthritis in the rabbit: its relationship to human joint pathology Br J Clin Pathol 40 1986 21 31
162. Mankin H.J. Dorfman H. Lippiello L. Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteoarthritic human hips. II. Correlation of morphology with biochemical andmetabolic data J Bone Joint Surg Am 53 1971 523 537
163. AAS Ghosh P. Armstrong S. Read R. Numata Y. Smith S. McNair P Animal models of early ostecarthritis. Their use for the evaluation of potential chondroprotective agents Joint Destruction in Arthritis and Osteoarthritis 39 1993 195 206
164. Imai K. Ohta S. Matsumoto T. Fujimoto N. Sato H. Seik M. Expression of membrane type 1 matrix metalloproteinase and activation of progelatinase A in human osteoarthritic cartilage Am J Pathol 151 1997 245 256
165. Moskowitz R.W. Davis W. Sammarco J. Mast W. Chase S.W. Experimentally induced corticosteroid arthropathy Arthritis Rheum 13 1970 236 243
166. Oegema T.R. Jr Behrens E. Proteoglycan aggregate synthesis in normal and chronically hydrocortisone-suppressed rabbit articular cartilage Arch Biochem Biophys 206 1981 77
167. Kongtawelert P. Brooks P. Ghosh P. Pentosan polysulfate (Cartrophen) prevents the hydrocortisone induced loss of hyaluronac acid and proteoglycans from cartilage of rabbit joints as well as normalizes the keratan sulfate levels in their serum J Rheumatol 16 1989 1454 1459
168. Kongtawelert P. The development and application of immunosorbent assays for the quantitation of hyaluronan and sulphated polysaccharides Ph.D. thesis 1991 University of Sydney
169. Takagi T. Forrest M.J. Brooks P.M. A pharmacological and histological examination of the microcirculation of the rat subcutaneous air-pouch: microcirculation of the rat air-pouch Pathology 19 1987 294 298
170. Edwards J.C.W. Sedgwick A.D. Willoughby D.A. The formation of a structure with the features of synovial lining by subcutaneous injection of air: an in vivo tissue culture system J Pathol 134 1981 147 156
171. Forrest M.J Brooks P.M. Takagi T. Kowanko I. The subcutaneous air-pouch model of inflammation Greenwald R.A Diamond H.S. Handbook of animal models for rheumatic diseases 1987 CRC Press Boca Raton, FL 125 134
172. Francis D.J. Forrest M.J. Brooks P.M. Ghosh P. Retardation of articular cartilage degradation by glycosaminoglycan polysulfate, pentosan polysulfate, and DH-40J in the rat air pouch model Arthritis Rheum 32 1989 608 616
173. Francis D. Studies on articular cartilage turnover in an animal model of inflammation PhD Thesis 1991 University of Sydney
174. Kongtawelert P. Francis D.J. Brooks P.M. Ghosh P. Application of an enzyme-linked immunosorbent-inhibition assay to quantitate the release of KS peptides into fluids of the rat subcutaneousair-pouch model and the effects of chondroprotective drugs on the release process Rheumatol Int 9 1989 77 83
175. Page-Thomas D.P. Aspects of experimental inflammatory arthritis Rheumatoid Arthritis 1977 173 179
176. Smith M.M. Ghosh P. Numata Y. Bansal M.K. The effects of orally administered calcium pentosan polysulphate on inflammation and cartilage degradation produced in rabbit joints byintraarticular injection of a hyaluronate-polylysine complex Arthritis Rheum 37 1994 125 136
177. Smith M.M. Numata Y. Bowman L. Ghosh P. Preservation of chondrocyte and synoviocyte metabolism (cytoprotection) by oral calcium pentosan polysulphate in a lapine model of inflammatoryarthritis Osteoarthritis Cart 4 1996 ii iii
178. Conaghan P.G. Smith M.M. Brooks P. Ghosh P. Effects of calcium xylopyranose polysulphate in an animal model of inflammation Osteoarthritis Cartilage 5 1997 62
179. Pritzker K.P. Animal models for osteoarthritis: processes, problems and prospects Ann Rheum Dis 53 1994 406 420
180. Myers S.L. Brandt K.D. O'Connor B.L. Visco D.M. Albrecht M.E. Synovitis and osteoarthritic changes in canine articular cartilage after anterior cruciate ligament transection: effect of surgical hemostasis Arthritis Rheum 33 1990 1406 1415
181. Soren A. Klein W. Huth E. The synovial changes in post-traumatic synovitis and osteoarthritis Rheumatol Rehabil 17 1978 38 44
182. Altman R.D. Gray R. Inflammation in osteoarthritis Clin Rheum Dis 11 1985 353 365
183. Myers S.L. Brandt K.D. Ehlich J.W. Braunstein E.M. Shelbourne K.D. Hec D.A. Synovial inflammation in patients with early osteoarthritis of the knee J Rheumatol 17 1990 1662 1669
184. Houssiau F.A. Devogelaer J-P. Van Damme J. de Deuxchaisnes C.N. Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides Arthritis Rheum 31 1988 784 788
185. Brozik M. Rosztoczy I. Meretey K. Balint G. Gaal M. Balogh Z. Interleukin 6 levels in synovial fluids of patients with different arthritides: correlation with local IGM rheumatoid factor and systemic acutephase protein production J Rheumatol 19 1992 63 68
186. Kuryliszyn-Moskal A. Comparison of blood and synovial fluid lymphocyte subsets in rheumatoid arthritis and osteoarthritis Clin Rheumatol 14 1995 43 50
187. Hrycaj P. Stratz T. Kovac C. Mennet P. Müller W. Microheterogeneity of acute phase proteins in patients with clinically active and clinically nonactive osteoarthritis Clin Rheumatol 14 1995 434 440
188. Schlaak J.F. Pfers I. Meyer zum Biischenfelde K-H. Märker-Hermann E. Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies Clin Exp Rheumatol 14 1996 155 162
189. Wagner S. Fritz P. Einsele H. Sell S. Saal J.G. Evaluation of synovial cytokine patterns in rheumatoid arthritis and osteoarthritis by quantitative reverse transcription polymerase chain reaction Rheumatol Int 16 1997 191 196
190. Roivainen A. Söderstrom K.O. Pirila L. Aro H. Kortekangas P. Merilahti-Palo R. Oncoprotein expression in human synovial tissue: an immunohistochemical study of different types of arthritis Br J Rheumatol 35 1996 933 942
191. Marok R. Winyard P.G. Coumbe A. Kus M.L. Gaffney K. Blades S. Mapp P.I. Activation of the transcription factor nuclear factor-kB in human inflamed synovial tissue Arthritis Rheum 39 1996 583 591
192. Lohmander L.S. Dahlberg L. Ryd L. Heinegård D. Increased levels of proteoglycan fragments in knee joint fluid after injury Arthritis Rheum 32 1989 1434 1442
193. Saxne T. Heinegård D. Synovial fluid analysis of two groups of proteoglycan epitopes distinguishes early and late cartilage lesions Arthritis Rheum 35 1992 385 390
194. Lohmander L.S. Articular cartilage and osteoarthrosis: the role of molecular markers to monitor breakdown, repair and disease J Anat 184 1994 477 492
195. Dahlberg L. Friden T. Roos H. Lark M.W. Lohmander L.S. Longitudinal study of cartilage matrix metabolism in patients with cruciate ligament rupture: synovial fluid concentrations of aggrecan fragments, stromelysin-1 and tissue inhibitor of metalloproteinase-1 Br J Rheumatol 33 1994 1107 1111
196. Lohmander L.S. Roos H. Dahlberg L. Hoermer L.A. Lark M.W. Temporal patterns of stromelysin-1, tissue inhibitor, and proteoglycan fragments in human knee joint fluid after injury to the cruciate ligament ormeniscus J Orthop Res 12 1994 21 28
197. Glant T.T. Mikecz K. Kuettner K.E. Thonar E.J.-M.A. Immune response to cartilage proteoglycans in inflammatory canimal models and human diseases Woessner F. Howell D. Joint cartilage degradation: basic and clinical aspects 1992 Dekker New York 435 473
198. Golds E.E. Poole A.R. Connective tissue antigens stimulate collagenase production in arthritic diseases Cell Immunol 86 1984 190 205
199. Hanauske-Able H.M. Pontz B.F. Schorlemmer H.U. Cartilage specific collagen activates macrophages and the alternative pathway of complement: evidence for an immunopathogenic concept of rheumatoidarthritis Ann Rheum Dis 41 1982 168 176
200. Alsalameh S. Mollenhauer J. Hain N. Stock K-P. Kalden J.R. Burmester G.R. Cellular immune response toward human articular chondrocytes: T cell reactivities against chondrocyte and fibroblast membranes in destructive jointdiseases Arthritis Rheum 33 1990 1477 1486
201. Banerjee S. Poole A.R. Immunity to cartilage proteoglycans J Rheumatol 19 1992 36 39
202. Charriere G. Hartmann D.J. Vignon E. Ronziere M-C. Herbage D. Ville G. Antibodies to type I, II, IX and XI collagen in the serum of patients with rheumatic diseases Arthritis Rheum 31 1988 325 332
203. Evans C.H. Mazzocchi R.A. Nelson D.D. Rubash H.E. Experimental arthritis induced by intruarticular injection of allogenic cartilaginous particles into rabbit knees Arthritis Rheum 27 1984 200 207
204. Glant T. Buzas E.I. Finnegan A. Negroiu G. Cs-Szabo G. Mikecz K. Critical roles of glycosaminoglycan side chains of cartilage proteoglycans (aggrecan) in antigen recognition and presentation J Immunol 160 1998 3812 3819
205. Yoo J.U. Kresina T.F. Malemud C.J. Goldberg V.M. Epitopes of proteoglycans eliciting an anti-proteoglycan response in chronic immune synovitis Proc Natl Acad Sci USA 84 1987 832 836
206. Kresina T.F. Yoo J.U. Glodberg V.M. Evidence that a Immoral immune-response to autologous cartilage proteoglycan can participate in the induction of cartilage pathology Arthritis Rheum 31 1988 248 257
207. Friedlaender G.E. Ladenbauer-Bellis I.M. Chrisman O.D. Immunogenicity of xenogeneic cartilage matrix components in a rabbit model Yale J Biol Med 56 1983 211 217
208. Gurr E. Ahrens A. Lonneman G. Delbruck A. Increased interleukin-1-beta production of macrophages by proteoglycan fragments deriving from articular cartilage in vitro Agents Actions 29 1990 117 119
209. Holmdahl R. Malmstrom V. Vourio E. Autoimmune recognition of cartilage collagens Ann Med 25 1993 251 264
210. Kalbhen D.A. The biochemical and pharmacological basis of the antiphlogistic/anfrheumatic effect of pentosan polysulphate Wein Klin Wochenschr 90 1978 101 105
211. Kalbhen D.A. Biochemisch-phannakologische Grundlagen zur antiphlogistisch-antirheumatischen Wirkung von Pentosanpolysulfat Wien. Klin Wochenschr 90 1978 101 105
212. Kalbhen D.A. Entzündungshemmung durch Pentosanpolysulfat Dtsch Med Wochenschr 97 1972 1 3
213. Kalbhen D.A. Pharmacological studies on the antiinflammatory effect of a semi-synthetic polysaccharide (pentosan polysulfate) Pharmacology 9 1973 74 79
214. Kalbhen D.A. Clausen H. Domenjoz R. Erste Untersuchungen zur entzundungshemmenden Wirkung von Pentosanpolysulfat auf verschiedene Odemformen der Rattenpfote Arzneimittelforschung 20 1970 1872 1874
215. Kalbhen D.A. Fischer W. Pharmakologische Untersuchungen zur entzündungshemmenden Wirkung von Pentosanpolysulfat (SP54) in Kombination mit anderenAnalgetika/Antiphlogistika Arzneimittelforschung 23 1973 712 718
216. Kalbhen D.A Van Heck H.J. Zur antiphlogistischen Wirkung von Pentosanpolysulfat auf das experimentelle Pfotenödem der Ratte Arzneimittelforschung 21 1971 1608 1612
217. Walb D. Loos M. Hadding U. Antikomplementare Wirkung eines semisynthetischen Pentosan-Polysulfo-Esters In-vitro-Untersuchungen uber Angriffspunkt und Wirkungsunterschiede zumHeparin Zschr Naturforsch 26 1971 403 408
218. Berthoux F.C Freyria A-M. Traeger J. Anticomplementary activity of a polyanion. Pentosan poly sulfoester. II. Mode of action and in vitro inhibition of human complement hemolyticactivity Pathol Biol 25 1977 105 108
219. Berthoux F.C. Freyria A-J. Traeger J. Anticomplementary activity of a polyanion, pentosan poly-sulfoester. III. Mechanism of functional inactivation of the different properdin andcomplement system molecules Pathol Biol 25 1977 179 184
220. Berthoux F.C. Freyria A-M. Zech P-Y. Traeger J. Anticomplementary activity of a polyanion: pentosan-polysulfoester. I. in vitro study and in vivo trial in human glomerulonephritis Pathol Biol 25 1977 33 36
221. Kilgore K.S. Naylor K.B. Tanhehco E.J. Park J.L. Booth E.A. Washington R.A. The semisynthetic polysaccharide pentosan polysulphate prevents complement-mediated myocardial injury in rabbit perfused heart J Pharm Exp Ther 285 1998 987 994
222. Smith MM, Ghosh P, Numata Y, Conaghan P, Calciumxylopyranose polysulfate (CaXPS) modulates cytokine, NO and disease activity in a new rat model of inflammatory arthritis. Osteoarthritis and Cartilage (in press).
223. Grabowski P.S. Wright P.K. Vanthof R.J. Helfrich M.H. Ohshima H. Ralston S.H. Immunolocalization of inducible nitric oxide synthase in synovium and cartilage in rheumatoid arthritis and osteoarthritis Br J Rheumatol 36 1997 651 655
224. Häuselmann H.J. Oppliger L. Michel B.A. StefanovicRacic M. Evans C.H. Nitric oxide and proteoglycan biosynthesis by human articular chondrocytes in alginate culture FEBS Lett 352 1994 361 364
225. Bansal M. Smith M.M. Numata Y. Ghosh P. The effects of CaPPS on inflammatory mediators in the rat subcutaneous air-pouch model of inflammation Curr Ther Res 54 1993 714 730
226. Yoshida K. Kobayashi K. Yamagata N. Iwabuchi H. Katsura T. Sugihara S. Inflammatory cytokines and enzymes in synovial fluid of patients with rheumatoid arthritis and other arthritides Int Arch Allergy Immunol 98 1992 286 292
227. Venn G. Nietfeld J.J. Duits A.J. Brennan F.M. Arner E. Covington M. Elevated synovial fluid levels of interleukin-6 and tumor necrosis factor associated with early experimental canine osteoarthritis Arthritis Rheum 36 1993 819 826
228. Bender S. Haubeck H-D. Van de Leur E. Dufhues G. Schiel X. Lauwerijns J. Interleukin-1-beta induces synthesis and secretion of interleukin-6 in human chondrocytes FEBS Lett 263 1990 321 324
229. Guerne P.A. Carson D.A. Lotz M. IL-6 production by human articular chondrocytes: modulation of its synthesis by cytokines, growth-factors, and hormones in vitro J Immunol 144 1990 499 505
230. van de Loo F.A.J. Kuiper S. van Enckevort F.H.J Arntz O.J. van den Berg W. Interleukin-6 reduces cartilage destruction during experimental arthritis Am J Pathol 151 1997 77 91
231. Ito A. Itoh Y. Sasaguri Y. Morimatsu M. Mori Y. Effects of interleukin-6 on the metabolism of connective tissue components, in rheumatoid synovial fibroblasts Arthritis Rheum 35 1992 11197 11201
232. Schindler R. Mancilla J. Endres S. Ghorbani G. Clark S. Dinarello C.A. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF Blood 75 1990 40 47
233. Sato T. Ito A. Mori Y. Interleukin 6 enhances the production of tissue inhibitor of metalloproteinases (TIMP) but not that of matrix metalloproteinases by humanfibroblasts Biochem Biophys Res Commun 170 1990 824 829
234. Theisen-Popp P. Pape H. Muller-Peddinghaus R. Interleukin-6 (IL-6) in adjuvant arthritis of rats and its pharmacological modulation Int J Immunol 14 1992 565 571
235. Balazs E.A. Briller S.O. Denlinger J.L. Na-hyaluronate molecular size variations in equine and human arthritic synovial fluids and the effect on phagocytic cells Semin Arthritis Rheum Suppl 1 1980 141 143
236. Balazs E.A. Denlinger J.L. Clinical uses of hyaluronan Evered D. Whelan J. Ciba Foundation Symposium The biology of hyaluronan 1989 Wiley and Sons Chichester 265 280
237. Balazs E.A. Denlinger J.L. Sodium hyaluronate and joint function Equine Vet Sci 5 1985 217 228
238. Mabuchi K. Tsukamoto Y. Obara T. Yamaguchi T. The effect of additive hyaluronic acid on animal joints with experimentally reduced lubricating ability J Biomed Mater Ref 28 1994 865 870
239. Cullis-Hill D. Ghosh P. The role of hyaluronic acid in joint stability: a hypothesis for hip displasia and allied disorders Med Hypothesis 23 1986 171 185
240. Duffy J.M. McNally G.M. Ogorman A. Spedding P.L. Grimshaw J. Grimshaw I.T. Viscometric studies of pathological human synovial fluids J Orthopedic Rheumatology 7 1994 99 106
241. Obara T. Mabuchi K. Iso T. Yamaguchi T. Increased friction of animal joints by experimental degeneration and recovery by addition of hyaluronic acid Clin Biomech 12 1997 246 252
242. Peyron J.G. Intraarticular hyaluronan injections in the treatment of osteoarthritis. State-of-the-art review J Rheumatol 20 1993 10 15
243. Dahl L.B. Dahl I.M.S. Engstrom-Laurent A. Granath K. Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies Ann Rheum Dis 44 1985 817 822
244. Ghosh P. Osteoarthritis and hyaluronan: palliative or disease modifying treatment? Semin Arthritis Rheum 22 1993 1 3
245. Ghosh P. The role of hyaluronic acid (hyaluronan) in health and disease: interactions with cells, cartilage and components of synovial fluid Clin Exp Rheumatol 12 1994 75 82
246. Ghosh P. Hutadilok N. Adam N. Lentini A. Interaction of hyaluronan (hyaluronic acid) with phospholipids as determined by gel permeation chromatography, multi-angle laser-lightscattering photometry and 1H-NMR spectroscopy Int J Biol Macromol 16 1994 237 244
247. Underhill C. CD44: the hyaluronan receptor J Cell Sci 103 1992 293 298
248. Culty M. O'Mara T.E. Underhill C.B. Yeager H. Jr Swartz R.P. Hyaluronan receptor (CD44) expression and function in human peripheral blood monocytes and alveolar macrophages J Leukoc Biol 56 1994 605 611
249. Culty M. Miyake K. Kincade P.W. Silorski E. Butcher E.C. Underhill C. The hyaluronate receptor is a member of the CD44 (H-CAM) family of cell-surface glycoproteins J Cell Biol 111 1990 2765 2774
250. Laurent U.B.G. Fraser J.R.E. Engström-Laurent A. Reed R.K. Dahl L.B. Laurent T.C. Catabolism of hyaluronan in the knee joint of the rabbit Matrix 12 1992 130 136
251. Hua Q. Knudson C.B. Knudson W. Internalization of hyaluronan by chondrocytes occurs via receptor mediated endocytosis J Cell Sci 106 1993 365 375
252. Henderson B. The biochemistry of the human synovial lining with special reference to alterations in metabolism in rheumatoid arthritis Pathol Res Pract 172 1981 1 24
253. Henderson B. Edwards J.C.W. Function of synovial lining The synovial lining in health and disease 1987 Chapman and Hall London 41 74
254. Smith M.M. Ghosh P. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment Rheumatol Int 7 1987 113 122
255. Edwards J.C.W. Synovial intimal fibroblasts Ann Rheum Dis 54 1995 395 397
256. Vuorio E. Einola S. Hakkarainen S. Penttinen R. Synthesis of underpolymerised hyaluronic acid by fibroblasts cultured from rheumatoid and non-rheumatoid synovitis Rheumatol Int 2 1982 97 102
257. Hutadilok N. Smith M. Cullis-Hill D. Ghosh P. Pentosan polysulphate stimulates hyaluronate and DNA synthesis in synovial fibroblasts and partially reduces the suppressive effect of hydrocortisone on fibroblast metabolism Curr Ther Res 44 1988 845 860
258. Francis D.J. Hutadilok N. Kongtawelert P. Ghosh P. Pentosan polysulphate and glycosaminoglycan polysulphate stimulate the synthesis of hyaluronan in vivo Rheumatol Int 13 1993 61 64
259. Verbruggen G. Veys E.M. Intea-articular injection of pentosanpolysulphate results in increased hyaluronan molecular weight in joint fluid Clin Exp Rheumatol 10 1992 249 254
260. Adam N. Ghosh P. Swain M. Rasaratnam I. Ryan P. The effects of intra-articular pentosan polysulphate (Cartrophen) on synovial fluid visco-elasticity and hyaluronan molecular weight in patients with gonarthritis Osteoarthritis Cart 4 1996 viii
261. Ghosh P. Hutadilok N. Interactions of pentosan polysulfate with cartilage matrix proteins and synovial fibroblasts derived from patients with osteoarthritis Osteoarthritis Cart 4 1996 43 53
262. Smith M.M Numata Y. Bowman L. Ghosh P. Calcium pentosan polysulfate given orally to rabbits with inflamed knee joints abrogates interleukin-l-induced antiproliferative effects and reduces nitric oxide but not interleukin-6 activity in ex vivo cultures of synovial fibroblasts Arthritis Rheum 38 1995 1312
263. Harrison M.H.M. Schajowicz F. Trueta J. Osteoarthritis of the hip: a study of the nature and evolution of the disease J Bone Joint Surg Br 35 1953 598 626
264. Arnoldi C.C. Vascular aspects of degenerative joint disorders Acta Orthop Scand 65 1994 1 82
265. Arnoldi C.C. Lemberg R.K. Linderholm H. Intraosseous hypertension and pain in the knee J Bone Joint Surg Br 57 1975 360 363
266. Bjorkstrom S. Goldie I.F. Wetterquist H. Intramedullary pressure of the patella in chondromalacia Arch Orthop Trauma Surg 97 1980 81 88
267. Bunger C. Harving S. Bunger E.H. Intraosseous pressure in the patella in relation to simulated joint effusion and knee position Acta Orthop Scand 53 1982 745 751
268. Brookes M. The blood supply to bone 1971 Butterworths London 234 302
269. Kenzora G. Steele R.E. Yosipovitch Z.H. Glimcher M.J. Experimental osteonecrosis of the femoral head in adult rabbits Clin Orthop 130 1978 8 15
270. Arnoldi C.C. Linderholm H. Mussbichler H. Venous engorgement and intraosseous hypertension in osteoarthritis of the hip J Bone Joint Surg Br 54 1972 409 421
271. Kiaer T. Grønlund J. Sørensen K.H. Intraosseous pressure and partial pressures of oxygen and carbon dioxide in osteoarthritis Semin Arthritis Rheum 18 1989 57 60
272. Starklint H. Lausten G.S. Arnoldi C.C. Microvascular obstruction in avascular necrosis: inmiunobistochemistry of 14 femoral heads Acta Orthop Scand 66 1995 9 12
273. Brookes M. The vascular factor in osteoarthritis Surg Gynecol Obstet 123 1966 1255 1260
274. Cheras P.A. Whitaker A.N. Blackwell E.A. Sinton T.J. Chapman M.D. Peacock K.A. Hypercoagulability and hypofibrinolysis in primary osteoarthritis Clin Orthop 334 1997 57 67
275. Hessel L.W. Kluft C. Advances in clinical fibrinolysis Clin Haematol 15 1986 443 463
276. Perez R.L. Roman J. Fibrin enhances the expression of IL-1 beta by human peripheral blood mononuclear cells: implications in pulmonary inflammation J Immunol 154 1995 1879 1887
277. Hopper K.E. Geczy C.L. Davies W.A. A mechanism of migration inhibition in delayed-type hypersensitivity reactions J Immunol 126 1981 1052 1058
278. Ali H. Haribabu B. Richardson R.M. Snyderman R. Mechanisms of inflammation and leukocyte activation Med Clin North Am 81 1997 1 28
279. Downing L.J. Wakefield T.W. Strieter R.M. Prince M.R. Londy F.J. Fowlkes J.B. Anti-P-selectin antibody decreases inflammation and thrombus formation in venous thrombosis J Vasc Surg 25 1997 816 827
280. Esmon C.T. Inflammation: they're not just for clots anymore Curr Biol 5 1995 743 746
281. Arnoldi C.C. Reimann I. Bretlau P. The synovial membrane in human coxarthrosis: light and electron microscopic studies Clin Orthop 148 1980
282. Freyburger G. Larrue F. Larrue J. Manciet G. Roudaut M.F. Boisseau M.R. Effect of pentosan-polysulfate on the haemorheological parameters in elderly patients: possible role of leucocyte arachidonic acid metabolism Thromb Res Suppl VI 1986 46
283. Freyburger G. Larrue F. Manciet G. Lorient-Roudaut M.F. Larrue J. Boisseau M.R. Hemorheological changes in elderly subjects: effect of pentosan polysulfate and possible role of leucocyte arachidonic acid metabolism Thromb Haemost 57 1987 322 325
284. Szirmai I. Kamondi A. Magyar H. JuhAsz C. Untersuchungen von Patienten mit zerebraler Ischärnie unter Peutosanpolysulphat (SP54) Investigations in patients with cerebral ischemia treated with pentosan polysulfate (SP54) Perfusion 6 1993 314 320
285. Vinazzer H. Prevention of recurrence of cerebrovascular thromboses: a randomized comparative study of acetylsalicylic acid and sodium pentosan polysulfate Fortschr Med 105 1987 79 83
286. Losonczy H. Nagy I. Dávid M. Effects of various doses of SP54 on fibrinolytic activity in patients with thrombotic diseases Folia Haematol Leipzig 115 1988 388 393
287. Losonczy H. Dávid M. Nagy I. Effect of pentosan polysulfate on activated partial thromboplastin time, thrombin time, euglobulin clot lysis, and on tissue-type plasminogenactivator and plasminogen activator inhibitor activities in patients with thromboembolic disease Semin Thromb Hemost 17 1991 394 398
288. Kiesel J. Harbauer G. Wenzel E. Pindur G. Bohnerth S. Comparison of the effects of sodium pentosanpolysulfate and unfractionated heparin on venous thrombosis: an experimental study in rats Thromb Res 64 1991 301 308
289. Kollár L. Rozsos I. István M. Kiss T. Pentosanpolysulfat bei peripherer arterieller Verschlußkrankheit im Stadium II nach Fontaine. Randomisierte, plazebo-kontrollierte DoppelblindStudie mit Cross-over Perfusion 2 1989 52 56
290. Maffrand J-P. Herbert J-M. Bernat A. Defreyn G. Delebassee D. Savi P. Experimental and clinical pharmacology of pentosan polysulfate Semin Thromb Hemost 17 1991 186 198
291. Klinger M.H.F. Platelets and inflammation Anat Embryol 196 1997 1 11
292. Messmore H.L. Griffin B. Koza M. Seghatchian J. Fareed J. Coyne E. Interaction of heparinoids with platelets: comparison with heparin and low molecular weight heparins Semin Thromb Hemost 17 1991 57 59
293. Messmore H.L. Jr Griffin B. Fareed J. Coyne E. Seghatchian J. In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets Ann NYAcad Sci 556 1989 217 232
294. Frandoli G. Spreafico P.L. Lampugnani P. Tammaro A.E. Action on fibrinolysis and platelet aggregation of a synthetic, heparin-like sulfated polyanion (SP 54) given orally and parenterally, as relatedto lipidic fractions: trials on long-term prophylactic treatment under double-blind conditions Arzneimittelforschung 22 1972 759 763
295. Schumacher K.A. Classen H.G. The preventative effect of a low-molecular weight pentosan-polysulphate on DAS-induced increase in pulmonary vascular resistance caused by platelet-aggregation Arzeimittelforschung 23 1973 431 433
296. Vinazzer H. Haas S. Stemberger A. Influence on the clotting mechanism of sodium pentosan polysulfate (SP54) in comparison to commercial beef lung sodium heparin Thromb Res 20 1980 57 68
297. Dunn F. Soria J. Soria C. Thomaidis A. Tobelem G. Caen J.P. Fibrinogen binding on human platelets: influence of different heparins and of pentosane polysulfate Thromb Res 29 1983 141 148
298. Kindness G. Williamson F.B. Long W.F. Effects of a sulphated xylan on aggregation of human blood platelets Thromb Res 16 1979 97 105
299. Cheras P.A. Nielsen G.V.L. Blackwell E.A. Whitaker A.N. Peacock K.A. Smith K.R. Role of hyperlipidemia, hypercoagulability and hypofibrinolysis in osteoarthritis: results of pentosan polysulphate treated osteoarthritic dogs Osteoarthritis Cartilage 5 1997 38
300. Soria C. Soria J. Ryckewaert J.J. Holmer E. Caen J.P. Anticoagulant activities of a pentosane polysulphate: comparison with standard heparin and a fraction of low molecular weight heparin Thromb Res 19 1980 455 463
301. Czapek E.E. Kwaan H.C. Szczecinski M. The effect of a sulfated polysaccharide on antithrombin III J Lab Clin Med 95 1980 783 790
302. 125I]-thrombin with antithrombin III or heparin cofactor II of human plasma Eur J Drug Metab Pharmacokinet 20 1995 73 77
303. Thomas D.P. Barrowcliffe T.W Merton R.E. Stocks J. Dawes J. Pepper D.S. In vivo release of anti-Xa clotting activity by a heparin analogue Thromb Res 17 1980 831 840
304. Ryde M. Eriksson H. Tangen O. Studies on the different mechanisms by which heparin and polysulphated xylan (PZ 68) inhibit blood coagulation in man Thromb Res 23 1981 435 445
305. Scully M.F. Ellis V. Kakkar V.V. Pentosan polysulphate: activation of heparin cofactor II or antithrombin III according to molecular weight fractionation Thromb Res 41 1986 489 499
306. Scully M.F Kakkar V.V. The antiheparin effect of a heparinoid, pentosan polysulphate: investigation of a mechanism Biochem J 218 1984 657 665
307. Scully M.F Kakkar V.V. Identification of heparin cofactor II as the principal plasma cofactor for the antithrombin activity of pentosan polysulphate (SP54) Thromb Res 36 1984 187 194
308. Scully M.R. Kinetic considerations on the physiologic control of thrombin and Factor Xa Semin Thromb Hemost 18 1992 218 223
309. Ofosu F.A. Fernandez F. Anvari N. Caranobe C. Dol F. Cadroy Y. Further studies on the mechanisms for the antithrombotic effects of sulfated polysaccharides in rabbit Thromb Haemost 60 1988 188 192
310. Ofosu F.A. Modi G.J. Hirsh J. Buchanan M.R. Blajchman M.A. Mechanisms for inhibition of the generation of thrombin activity by sulfated polysaccharides Ann NY Acad Sci 485 1986 41 55
311. Jesty J. Maynard J.R. Radcliffe R.D. Silverberg S.A. Pitlick F.A. Menerson Y. Reich E. Rifkin D.B Shaw E. Proteases and biological control 1975 Cold Spring Harbor Laboratory Cold Spring Harbor, NY 171 189
312. Sie P. Fernandez F. Caranobe C. Gabaig A.M. Boneu B. Inhibition of thrombin-induced platelet aggregation and serotonin release by antithrombin III and heparin co-factor II in the presence of standard heparin, dermatan sulfate and pentosan polysulfate Thromb Res 35 1984 231 236
313. Sie P. Fernandez F. Ofosu F. The relative importance of anti-thrombin II for the anticoagulant effect of heparin, dermatan sulfate (DS) and pentosan polysulfate (PPS) Thromb Haemost 54 1985 204
314. Sie P. Ofosu F. Fernandez F. Buchanan M.R. Petitou M. Boner B. Respective role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and of various sulphated polysaccharides Br J Haematol 64 1986 707 714
315. Vinazzer H. Effect of pentosan polysulphate on fibrinolysis: basic tests and clinical application Semin Thromb Hemost 17 1991 375 378
316. Vinazzer H. Klinische untersuchungen zur fibrinolytischen wirkung von pentosanpolysulfat Folia Haematol 113 1986 272 277
317. Fischer A-M. Barrowcliffe T.W. Thomas D.P. A comparison of pentosan polysulphate (SP54) and heparin I mechanism of action on blood coagulation Thromb Haemostas 47 1982 104 108
318. Fischer A.M Dautzenberg M.D. Aurousseau M.H. Bëguin S. Goudeman J. Hemker H.C. Comparison between the effect of pentosan polysulphate heparin and antithrombin III injections in antithrombin III deficient patients Thromb Res 37 1985 295 307
319. 125I thrombin with andthrombin-III or heparin-cofactor-II of human plasma Eur J Drug 20 1995 162
320. Sampol J. Angles-Cano E. Benchimol P. Diner H. Boutiere B. Sultan Y. Pentosan polysulfate (SP54): mechanism of action on blood coagulation and fibrinolysis after intravenous injection of four different concentrationsin healthy volunteers Progress in Fibrinolysis VII 1985 316 318
321. Ofosu F.A. Sie P. Modi G.J. Fernandez F.A. Buchanan M.R. Blajchman M.A. The inhibition of thrombindependent positive feedback reactions is critical to the expression of the anticoagulant effect of heparin Biochem J 243 1987 579 588
322. Krupinsk K. Basicmic M. Lindhoff R. Breddin H.K. Inhibition of coagulation and platelet-adhesion to extracellularmatrix by unfractionated heparin and a low-molecular-weight heparin Blot 61 1990 289 294
323. Halse T. Aktivierung der Fibrinolyse and Thrombolyse durch Polysaccharidschwefelsäureester (Heparin, Heparinoide) Arzneimittelforschung 12 1962 574 582
324. Köstering H. König F. Weber S. Warmarm E. Guerrero M. Einfluss von oral and transkuten appliziertem SP54 auf präformierte Thrombose im Tierversuch Med Welt 24 1973 139 140
325. Vinazzer H. Stemberger A. Haas S. Blümel G. Influence of heparin: of different heparin fractions and of a low molecular weight heparin-like substance on the mechanism of fibrinolysis Thromb Res 27 1982 341 352
326. (abstr) Marsh N.A. Gaffney P.J. The effect of pentosan polysulphate (SP54) on the fibrinolytic enzyme system: a proposal for the mode of action Prog Fibrinolysis VII 1985
327. Marsh N.A. Gaffney P.J. The effect of pentosan polysulphate (SP54) on the fibrinolytic enzyme system: an experimental animal study Folia Haematol 113 1986 255 261
328. Gaffney P.J. Marsh N.A. The effect of pentosan polysulphate (SP54) on the human fibrinolytic system Folia Haematol 113 1986 262 271
329. Sié P. Albarede J.L. Robert M. Bouloux C. Lansen J. Chigot C. Tolerance and biological activity of pentosan polysulfate after intramuscular or subcutaneous administration for ten days in human volunteers Thromb Haemost 55 1986 86 89
330. Marsh N. Gaffney E. Some observations on the release of extrinsic and intrinsic plasminogen activators during exercise in man Haemostasis 9 1980 238 247
331. Barrowcliffe T.W. Gray E. Merton R.E. Dawes J. Jennings C.A. Hubbard A.R. Anticoagulant activities of pentosan polysulphate (Hëmoclar) due to release of hepatic triglyceride lipase (HTGL) Thromb Haemost 56 1986 202 206
332. Delvos U. Paul J.E. Muller-Berghaus G. Effect of the heparinoid pentosan polysulphate (SP 54) on the functional properties of cultured bovine aortic endothelial cells Blut 51 1985 127 136
333. Vinazzer H.A. Clinical and experimental data on the fibrinolytic action of pentosan polysulphate Progress in Fibrinolysis VII 1985 319 321
334. Klöcking H-P. Influence of pentosan polysulfate sodium compared with other polyanionic compounds on the t-PA and PAL 1 activity Perfusion Suppl 2 1994 32 38
335. Klöcking H-P. Hauptmann J. Richter M. Profibrinolytic and anticoagulant properties of the pentosan polysulphate derivative bego 0391 XIth Meeting of the International Society of Haematology European and African Division Basel, Switzerland August 31 to September 6, 1991
336. Klöcking H-P. Acute t-PA releasing effect of supersulphated low molecular weight heparins Fibrinolysis 8 1994 75 77
337. Klöcking H-P. Markwardt F. Release of plasminogen activator by pentosan polysulphate Thromb Res 41 1986 739 744
338. Klöcking H-P. Richter M. Hauptmann J. Studies on profibrinolytic and anticoagulant properties of calcium pentosan polysulphate Naunyn Schmiedebergs Arch Pharmacol 344 1991 R54
339. Klöcking H-P. Influence of pentosan polysulfate sodium compared with other polyanionic compounds on the t-PA and PAI-1 activity Ann Hemat 70 Suppl I 1995 A39
340. Krupinski K. Breddin H.K. Casu B. Anticoagulant and antithrombotic effects of chemically modified heparins and pentosanpolysulfate Haemostasis 20 1990 81 92
341. Weichert W. Pauliks V. Breddin H.K. Laser-induced thrombi in rat mesenteric vessels and anti-thrombotic drugs Haemostasis 13 1983 61 71
342. Jamieson A. Alcock P. Tuffin D.P. The action of polyanionic agents defibrotide and pentosan polysulfate on fibrinolytic activity in the laboratory rat Fibrinolysis 10 1996 27 35
343. FitzGerald D.E. Szeto I.L.F. Spero J. Lewis J.H. The thrombolytic effect of heparin and a heparin-like substance, SP 54 Thromb Diath Haem 17 1967 418 422
344. Verbruggen G. Veys E.M. Ghosh P. Cullis-Hill D. Pentosanpolysulfate treatment in osteoarthritis, serological parameters which could correlate with clinical response Osteoarthritis Cart 2 1994 60
345. Jones J.P. Fat embolism and osteonecrosis Orthop Clin North Am 16 1985 595 633
346. Olivecrona T. Bengtsson-Olivecrona G. østergaad P. Liu G. Chevreuil O. Hultin M. New aspects of heparin and lipoprotein metabolism Haemostasis 23 1993 150 160
347. Brunaud M. Segal V. Ravold J. Raveux R. The clearing effect of xylane sulfate polyesters on plasma lipids Prog Biochem Pharmacol 3 1967 393 402
348. Raveux R. Ravold V. Segal V. Brunaud M. Studies on the effect of xylane sulfate polyesters on the lipid composition of blood serum in rats receiving a high-fat diet Prog Biochem Pharmacol 2 1967 451 458
349. Cullis-Hill D. Bellenger C. Bowman L. Ghosh P. Calcium pentosan polysuphate (CaPPS): an orally-active pleotropic osteoarthritis drug (POD) stimulates the release of superoxide dismutase (SOD) and lipases into canine plasma Rheumatology in Europe 24 1995
350. Orme C.E. Harris R.C. A comparison of the lipolytic and anticoagulative properties of heparin and pentosan polysulfate in the thoroughbred horse Acta Physiol Scand 159 1997 179 185
351. Williams S.P. Barrowcliffe T.W. The effects of postheparin plasma lipases on anti-XA clotting activity Thromb Res 37 1985 371 377
352. Zeller W. Schön H. Aladag I. Investigations on the treatment of the hyperlipaemic atherosclerosis with SP54 Med Welt 42 1964 2231 2238
353. Edelman J. Anderson J. Ghosh P. Disease modification in osteoarthritis: relationship of macrophage procoagulant activity and haematological parameter to symptoms in patientsreceiving pentosan polysulphate Osteoarthritis Cart 4 1996 iv v
354. Anderson J. Bansal M. Ghosh P. Stimulation of peripheral blood mononuclear cells by cartilage degradation products J Leukoc Biol 100 suppl 1 1993
355. Watson A.D.J. Nicholson A. Church D.B. Pearson M.R.B. Use of anti-inflammatory and analgesic drugs in dogs and cats Aust Vet J 74 1996 203 210
356. Read R.A. Cullis-Hill D. Jones M.P. Systemic use of pentosan polysulphate in the treatment of osteoarthritis J Small Anim Pract 37 1996 108 114
357. Bouck G.R. Miller C.W. Taves C.L. A comparison of surgical and medical treatment of fragmented coronoid process and osteochondritis dissecans of the canine elbow Vet Comp Orthop Traumatol 8 1995 177 183
358. Edelman J. March L. Ghosh P. A double-blind placebocontrolled clinical study of a pleiotropic osteoarthritis drug (pentosan polysulphate, Cartrophen) in 105 patients withosteoarthritis (OA) of the knee and hip joints Osteoarthritis Cartilage 2 1994 23
359. Bellamy N. Buchanan W.W. Goldsmith C.M. Campbell J. Stitt L.W. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy inpatients with osteoarthritis of the hip or knee J Rheumatol 15 1988 1833 1840
360. Verbruggen G, Ghosh P, Cullis-Hill D, Veys E, Xylan polysulphate has SMOAD activities in patients with inflammatory finger joint OA. Osteoarthritis and Cartilage (in press).
361. Rasaratnam I. Ryan P. Bowman L. Smith M. Ghosh P. A double-blind placebo-controlled study of intra-articular pentosan polysulphate (Cartrophen) in patients with gonarthritis: laboratory andclinical findings Osteoarthritis Cartilage 4 1996 vi vii
362. Kongtawelert P. Ghosh P. An enzyme-linked immunosorbent-assay for quantitation of hyaluronin (hyaluronic acid) in biological fluids Anal Biochem 178 1989 367 372
363. Nguyen Q. Murphy G. Roughley P.J. Mort J.S. Degradation of proteoglycan aggregate by a cartilage metaloproteinase: evidence for the involvement of stromelysin in the generation of link protein heterogeneity in situ Biochem J 259 1989 61 67
364. Fosang A.J. Last K. Knauper V. Neame P.J. Murphy G. Hardingham T.E. Fibroblast and neutrophil collagenases cleave at 2 sites in the cartilage aggrecan interglobular domain Biochem J 295 1993 273 276
365. Nguyen Q. Murphy G. Hughes C.E. Mort J.S. Roughley P.J. Matrix metalloproteinases cleave at two distinct sites on human cartilage link protein Biochem J 295 1993 595 598
366. Fosang A.J. Neame P.J. Last K. Hardingham T.E. Murphy G. Hamilton J.A. The interglobular domain of cartilage aggrecan is cleaved by pump, gelatinases, and cathepsin-B J Biol Chem 267 1992 9470 9474
367. Werb Z. ECM and cell surface proteolysis: Regulating cellular ecology Cell 91 1997 439 442
368. Okada Y. Konomi H. Yada T. Kimata K. Nagase H. Degradation of type IX collagen by matrix metalloproteinase 3 (stromelysin) from human rheumatoid synovial cells FEBS Lett 244 1989 473 476
369. Okada Y. Nakanishi I. Activation of matrix metalloproteinase 3 (stromelysin) and matrix metalloproteinase 2 (gelatinase) by human neutrophil elastase and cathepsin G FEBS Lett 249 1989 353 356
370. Wu J.J. Lark M.W. Chun L.E. Eyre D.R. Sites of stromelysin cleavage in collagen types II, IX, X and XI of cartilage J Biol Chem 266 1991 5625 5628
371. Fosang A.J. Last K. Neame P.J. Murphy G. Knauper V. Tschesche H. Neutrophil collagenase (MMP-8) cleaves at the aggrecanase site E(373)-A(374) in the interglobular domain of cartilage aggrecan Biochem J 304 1994 347 351
372. Cole A. Chubinskaya S. Huch K. Mikecz K. Kuettner K.E. Neutrophil collagenase (MMP-8) is expressed by human osteoarthritic chondrocytes Trans Comb Orthop Res Soc 2 1995 78
373. Flannery C.R. Sandy J.D. Identification of MMP-13 (collagenase-3) as the major metalloproteinase expressed by chondrocytes during retinoic acid-induced matrix catabolism Trans Orthop Res Soc 41 1995 102
374. Ries C. Petrides P.E. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease Biol Chem Hoppe-Seyler 376 1995 345 355
375. Mochan E. Keler T. Plasmin degradation of cartilage proteoglycan Biochim Biophys Acta 800 1984 312 315
376. Campbell I.K. Piccoli D.S. Butler D.M. Singleton D.K. Hamilton J.A. Recombinant human interleukin-1 stimulates human articular cartilage to undergo resorption and human chondrocytes to produce both tissue-type andurokinase-type plasminogen activator Biochim Biophys Acta 967 1988 183 194
377. Campbell I.K. Piccoli D.S. Roberts M.J. Muirden K.D. Hamilton J.A. Effects of tumor necrosis factor-alpha and factorbeta on resorption of human articular cartilage and production of plasminogen activator by humanarticular cartilage Arthritis Rheum 33 1990 542 552
378. Starkey P. Barrett A.J. Burleigh M.C. The degradation of articular collagen by neutrophil proteinases Biochim Biophys Acta 4 83 1977 386 397
379. Gadher S.J. Eyre D.R. Wotton S.F. Schmid T.M. Woolley D.E. Degradation of cartilage collagens type II, type IX, type X and type XI by enzymes derived from human articular chondrocytes Matrix 10 1990 154 163
380. Gadher S.J. Eyre D.R. Duance V.C. Wotton S.F. Heck L.W. Schmid T.M. Susceptibility of cartilage collagens type II, IX, X, and XI to human synovial collagenase and neutrophil elastase Eur J Biochem 175 1988 1 7
381. Rodgers K.J. Melrose J. Ghosh P. Biotin-labeled potato chymotrypsin inhibitor-1: a useful probe for the detection and quantitation of chymotrypsin-like serine proteinases on Western blots and its application in the detection of a serine proteinase synthesised by articular chondrocytes Anal Biochem 227 1995 129 134
382. Yamada H. Nakagawa T. Stephens R.W. Nagai Y. Proteinases and their inhibitors in normal and osteoarthritic articular cartilage Biomed Res 8 1987 289 300
383. Maciewicz R.A. Wotton S.F. Etherington D.J. Duance V.C. Susceptibility of the cartilage rollagens types types II, IX and XI to degradation by the cysteine proteinases, cathepsins B and L FEBS Lett 269 1990 189 193
384. Baici A. Hörler D. Lang A Merlin C. Kissling R. Cathepsin B in osteoarthritis: Zonal variation of enzyme activity in human femoral head cartilage Ann Rheum Dis 54 1995 281 288
385. Mort J.S. Recklies A.D. Poole A.R. Extracellular presence of the lysosomal proteinase Cathepsin B in rheumatoid synovium and its activity at neutral pH Arthritis Rheum 27 1984 509 515
386. Suzuki K. Shimizu K. Hamamoto T. Nakagawa Y. Murachi T. Yamamuro T. Characterization of proteoglycan degradation by calpain Biochem J 285 1992 857 862
387. Sapolsky A.I. Altman R.D. Howell DS. Cathepsin D activity in normal and osteoarthritic human cartilage Fed Proc 32 1973 1489 1493
388. Poole A.R. Hembry R.M. Dingle J.T. Cathepsin D in cartilage: the immunohistochemical demonstration of extracellular enzyme in normal and pathological conditions J Cell Sci 14 1974 139 161
389. (Suppl) Maciewicz R.A. Wardale R-J. Wotton S.F. Duance V.C. Etherington D.J. Mode of acativation of the precursor to cathepsin L: implication for matrix degradation in arthritis Bio Chem Hopp-Seyler 371 1990 223 228
390. Müller-Ladner U. Gay R.E. Gay S. Cysteine proteinases in arthritis and inflammation Perspect Drug Discovery Design 6 1996 87 98